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Cytokinesis involves temporally and spatially coordinated action of the cell cycle and cytoskeletal and membrane
systems to achieve separation of daughter cells. To dissect cytokinesis mechanisms it would be useful to have a
complete catalog of the proteins involved, and small molecule tools for specifically inhibiting them with tight temporal
control. Finding active small molecules by cell-based screening entails the difficult step of identifying their targets. We
performed parallel chemical genetic and genome-wide RNA interference screens in Drosophila cells, identifying 50
small molecule inhibitors of cytokinesis and 214 genes important for cytokinesis, including a new protein in the Aurora
B pathway (Borr). By comparing small molecule and RNAi phenotypes, we identified a small molecule that inhibits the
Aurora B kinase pathway. Our protein list provides a starting point for systematic dissection of cytokinesis, a direction
that will be greatly facilitated by also having diverse small molecule inhibitors, which we have identified. Dissection of
the Aurora B pathway, where we found a new gene and a specific small molecule inhibitor, should benefit particularly.
Our study shows that parallel RNA interference and small molecule screening is a generally useful approach to
identifying active small molecules and their target pathways.
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Introduction
Small molecule inhibitors are useful tools for studying
dynamic biological processes. Compared to mutations and
RNA interference (RNAi), cell-permeable small molecules
allow inhibition of protein function with precise temporal
control, and may also spur development of new therapeutics.
One approach to ﬁnding useful small molecules is phenotypic
screening, in which cells are treated with small molecules
from a library and scored for inhibition of the process of
interest. The rate-limiting step in this approach is identifying
the cellular targets of active small molecules. Traditionally,
the targets of small molecules have been identiﬁed by
methods based on physical afﬁnity, for example, afﬁnity
chromatography (Harding et al. 1989). These require chem-
ical modiﬁcation of the small molecule and suffer the
limitation that irrelevant proteins will bind in addition to
the authentic target. A complementary method is to use
information on the biological activity of the small molecule to
identify the cellular pathway it perturbs. In some cases an
educated guess can be successful (Mayer et al. 1999), but to be
generally useful, the biological activity of a small molecule
would need to be systematically compared to the effect of
perturbing different cellular pathways. Currently, the most
general method for systematically perturbing pathways and
collecting phenotypic information is RNAi, which can be
used to inhibit protein function on a genome-wide basis.
Here, we develop a parallel screening strategy for ﬁnding
small molecules that inhibit the biological process of
cytokinesis, the genes required for this process, and, by
cross-comparison of phenotypes, information on the protein
targets of the small molecules.
Cytokinesis is the ﬁnal step of cell division, when the
daughter cells are physically separated by constriction of a
cleavage furrow. Complex spatiotemporal coordination of
several cell systems, including the microtubule and actin
cytoskeletons, the cell cycle engine, and vesicle trafﬁcking, is
required for furrow positioning, assembly, ingression, and
eventual cell separation. Some important components of the
cleavage furrow, for example, actin (Schroeder 1973), Myosin
(Mabuchi and Okuno 1977), and Anillin (Oegema et al. 2000),
have been identiﬁed, as well as signaling systems that position
and regulate the furrow, such as Aurora B (Carmena and
Earnshaw 2003) and Polo (Carmena et al. 1998) kinases and
Rho family GTPases (Prokopenko et al. 2000). Since many of
these proteins also play roles in additional cellular processes,
analysis of their function in cytokinesis by genetic methods
can be difﬁcult, and small molecule tools would be useful. To
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Open access, freely available online PLoS BIOLOGYdate, only three cytokinesis proteins, actin, Myosin II, and
Aurora B kinase, have been targeted with small molecules, but
even this limited set has been very useful. For example, the
actin inhibitor cytochalasin was used to discover the central
role of actin in cytokinesis (reviewed in Peterson and
Mitchison 2002), and the Myosin II inhibitor, blebbistatin,
provided insight into the coordination of different processes
in cytokinesis (Straight et al. 2003). Small molecule inhibitors
of Aurora B kinase have recently been reported, but their
effect on cytokinesis has yet to be investigated in detail
(Ditchﬁeld et al. 2003; Hauf et al. 2003).
Although several key cytokinesis proteins are known, we
lack a complete list of proteins required for cytokinesis in any
organism. In a genome-wide study, 98 proteins were reported
to localize to the bud neck, the site of cytokinesis in
Saccharomyces cerevisiae (Huh et al. 2003), but their functional
roles have not yet been systematically investigated. A
proteomic screen that identiﬁed many components of
mammalian midbodies, organelle-like remnants of the cleav-
age furrow, was reported recently (Skop et al. 2004) and
several small-scale RNAi studies have been conducted in
Drosophila (Somma et al. 2002; Goshima and Vale 2003; Kiger
et al. 2003; Rogers et al. 2003). These screens identiﬁed genes
required for cytokinesis, but did not assay an entire genome.
Genome-wide RNAi screens have been carried out in
Caenorhabditis elegans and in Drosophila cells, but they did not
focus on genes required for cytokinesis (Kamath et al. 2003;
Boutros et al. 2004).
Results/Discussion
Parallel Screening Protocols
To identify all genes required for cytokinesis, and small
molecules that target their products, we developed an assay
for both comprehensive functional genomic and large-scale
chemical genetic screens in cultured Drosophila cells. We chose
this system because of both the availability of genome-wide
RNAi resources (Boutros et al. 2004) and the ease of RNAi in
Drosophila cells. Drosophila cells can take up long pieces of
double-stranded RNA (dsRNA) from the culture medium and
process them into small interfering RNAs without triggering
an interferon response, in contrast to mammalian cells
(Clemens et al. 2000; Elbashir et al. 2001). Furthermore, use
of a single targeting dsRNA is efﬁcient for the knockdown of
a speciﬁc gene in each experiment. Therefore, we were able
to screen a library of existing dsRNAs with an average length
of 408 bp (Hild et al. 2003) to functionally test nearly all
Drosophila genes for roles in cytokinesis.
Cells that undergo mitosis normally, but fail cytokinesis,
acquire two nuclei. This phenotype is a speciﬁc and
irreversible consequence of cytokinesis failure, and can be
scored by automated ﬂuorescence microscopy. Drosophila
Kc167 cells were cultured together with either gene-speciﬁc
dsRNAs or discrete small molecules in optical-bottom 384-
well plates. In total, we screened 19,470 dsRNAs covering
more than 90% of the annotated genome in triplicate at the
Drosophila RNAi Screening Center (http://www.ﬂyrnai.org)
and over 51,000 small molecules at the Institute of Chemistry
and Cell Biology (http://iccb.med.harvard.edu). The cells were
incubated for 4 d in the presence of dsRNAs to allow for
depletion and turnover of targeted gene products, or 2 d for
small molecules to permit each cell to complete at least one
cell cycle. After ﬁxation, cells were stained with amine-
reactive tetramethylrhodamine-NHS ester to visualize total
cytoplasm and Hoechst dye to visualize DNA. In the RNAi
screen, microtubules were visualized by immunoﬂuorescence.
Cells were imaged by automated ﬂuorescence microscopy,
and assay wells containing a high frequency of binucleate cells
were identiﬁed by a combination of automated image analysis
and visual inspection.
Small Molecule Screening Results
From approximately 51,000 small molecules that included a
mixture of commercial ‘‘drug-like’’ molecules, natural prod-
uct extracts, and natural-product-like libraries synthesized at
the Institute of Chemistry and Cell Biology (http://iccb.med.
harvard.edu), we identiﬁed 50 small molecule inhibitors of
cytokinesis, and selected 25 of the most potent and readily
available for further analysis (Table S1). This structurally
diverse group, which we named binucleines 1–25, included 12
small molecules from commercial libraries, ten known
bioactives, and three natural product extracts. We screened
at a nominal concentration of 12.5 lg/ml (approximately 25
lM) and retested the effect of our 25 small molecule
inhibitors on Drosophila tissue culture cells at three different
concentrations: 100 lM, 30 lM, and 10 lM (Table S1). To
determine cross-reactivity with other species, we also assayed
cytokinesis inhibition in HeLa (64%, 16/25 active) and BSC-1
(52%, 13/25 active) tissue culture cells as well as growth
inhibition in drug-sensitive S. cerevisiae (48%, 12/25 active)
(see Table S1).
Since most compounds currently known to inhibit cytoki-
nesis are natural product actin binders, we tested if the small
molecule inhibitors affected actin polymerization. Binu-
cleines 4, 6, 24, and 25 inhibited pyrene–actin polymerization
in a pure protein assay (data not shown). Binucleines 24 and
25 are the actin binders cytochalasin D and jasplakinolide,
which were included in our small molecule collection as
control compounds. Binucleine 4 is a natural product extract
from Ircinia ramosa, which contains swinholide A, a known
actin binder, as its active ingredient (F. C. Schroeder and J.
Clardy, personal communication). To learn more about the
cellular targets of the remaining compounds, we proceeded
with our plan to systematically compare small molecule and
RNAi phenotypes.
Genome-Wide RNAi Screening Results
We identiﬁed dsRNAs corresponding to 214 genes with
phenotypes important for cytokinesis (Table S2). Only
dsRNAs that resulted in a binucleate phenotype in at least
two of the three replicate screens were summarized in our
ﬁnal results (Table S3). These genes resulted in either a
strong, medium, or weak increase in frequency of binucleate
cells (Figure 1) and represented a diverse range of predicted
cellular functions (Figure 2; Table S4), reﬂecting the complex-
ity of cytokinesis. Of the RNAi phenotypes, 20% identiﬁed
genes previously directly implicated (Table S5 and references
therein) or involved in processes associated with cytokinesis.
Eleven of the strong phenotypes identiﬁed such genes,
including two copies of actin (Act57B and Act5C), Myosin
heavy chain (zipper), Anillin (scraps), a formin (diaphanous), Rho
GTPase (Rho1) and its known guanine nucleotide exchange
factor (pebble) and GTPase-activating protein (RacGAP50C), a
kinesin (pavarotti), Citron kinase (CG10522), Aurora B kinase
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gene essential for cytokinesis (CG4454, see discussion below),
increasing the number of speciﬁc essential proteins con-
ﬁrmed by RNAi to thirteen (the twelve genes listed above and
INCENP; see Table S5). Although required for cytokinesis
(Adams et al. 2001) and successfully resynthesized for later
experiments, INCENP was not identiﬁed in our screen
because of failure in INCENP dsRNA synthesis.
Cytokinesis is a complex, multistep process, unlikely to be
regulated and executed by only thirteen proteins, suggesting
that many other proteins with less stringent requirements are
also involved. Our screen identiﬁed 201 genes with a loss-of-
function phenotype of a medium or weakly penetrant
cytokinesis failure. Of these genes, 54 were predicted to
encode proteins with unknown function, including 25 that
were targeted with dsRNA on the basis of new gene model
predictions (Hild et al. 2003). The remaining genes had a
variety of predicted functions, including cell cycle regulation
and vesicle transport. Cytokinesis is known to require
insertion of new plasma membrane (Finger and White
2002), consistent with our identiﬁcation of genes involved
in vesicle transport (12 genes). We were surprised, however,
that this group included most of the components of the
coatomer complex COPI (5/7 COPI subunits). The COPI
complex is thought to be involved in retrograde transport
from Golgi apparatus to endoplasmic reticulum, and its role
in cytokinesis remains to be elucidated. An unexpected
functional group, identiﬁed mostly with weak phenotypes,
included genes involved in nucleic acid and protein synthesis
and degradation, including a large number of ribosomal
proteins. We subjected nine of these genes to further analysis.
In seven of nine cases, ﬁlamentous actin staining was very
weak, while other proteins such as tubulin and Myosin were of
normal abundance, suggesting that the phenotype may result
from low-level synthesis of actin or other cortical compo-
nents (data not shown). Since a library of a single long dsRNA
per gene was used in this screen, it is conceivable that some
phenotypes are due to off-target effects. The approximately
400-nt dsRNAs are processed into smaller small interfering
RNAs, and if appropriately processed, could cross-hybridize
partially or completely with identical sequences in mRNA
corresponding to other genes (Bartel 2004; Tijsterman and
Plasterk 2004). Of 214 dsRNAs identiﬁed in our screen, 57
had a potential 21-nt overlap with other genes (see Table S3).
In the majority of these cases (39/57), full-length dsRNA
corresponding to the potential cross-match gene did not
itself score. Some related genes, for example, the ﬁve copies
Figure 1. Distribution of Active Small Molecules and Genes Targeted by
RNAi Identified by Penetrance of Binucleate Phenotype and by
Phenotypic Classes
(A and B) Penetrance of binucleate phenotype for small molecules (A)
and RNAi hits (B). (A) For the small molecules, 24% (6/25) were strong
(s), 44% (11/25) medium (m), and 32% (8/25) weak (w). (B) For the
RNAi hits 6% (13/2114) were strong (s), 20% (43/214) medium (m),
and 74% (158/214) weak (w). In a weakly penetrant phenotype, the
binucleate level was increased by more than 1.25-fold relative to the
two neighboring wells in at least two experiments. In a medium
penetrance phenotype, the binucleate level was above 4%, or four
times as high as the neighboring wells. In a strongly penetrant
phenotype, the binucleate level was above 15%. The average
binucleate level in controls was approximately 1%.
(C and D) Phenotypic classes for small molecules (C) and genes
targeted by dsRNAs (D). (C) For the small molecules, 40% (10/25) were
binucleate (b; Figure 2A), 8% (2/25) binucleate with large, diffuse
DNA (d; Figure 2B), 28% (7/25) binucleate with low cell count (lc;
Figure 2C), and 24% (6/25) binucleate with microtubule extensions
(MT; Figure 2D). (D) For the RNAi hits, 51% (109/214) were binucleate
(b; Figure 2A), 2% (5/214) binucleate with large, diffuse DNA (d;
Figure 2B), 29% (62/214) binucleate with low cell count (lc; Figure
2C), and 12% (25/214) binucleate with microtubule extensions (MT;
Figure 2D). In addition, 5% (10/214) were binucleate with low cell
count and microtubule extensions, and 1% (3/214) were binucleate
with low cell count and large, diffuse DNA.
DOI: 10.1371/journal.pbio.0020379.g001
Figure 2. Predicted Functional Annotations of 214 Genes Associated
with RNAi Binucleate Phenotypes
Functional groups were assigned using Gene Ontology information
presented in FlyBase or the literature (see Table S4). Genes involved
in processes associated with cytokinesis are shown in shades of yellow,
nucleic acid and protein synthesis and degradation in shades of red,
and uncharacterized genes in shades of blue. The uncharacterized
genes encode protein sequences that predict recognizable domains
(‘‘putative domain’’), no recognizable domains (‘‘no recognized
domain’’), or new gene predictions from the reannotation of the
Drosophila genome used as the basis of the dsRNA library (‘‘new
annotation’’).
DOI: 10.1371/journal.pbio.0020379.g002
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Parallel Chemical and RNAi Screensof actin identiﬁed in our screen, show high homology and are
therefore expected to contain overlapping dsRNA sequences.
Comparison of RNAi Screen to Other Screens
Since one of our goals was to create an inventory of all
genes required for cytokinesis, it is important to evaluate the
success rate of the genome-wide RNAi screen with respect to
other published screens and to the cytokinesis literature in
general. Four small-scale screens have examined the role of
speciﬁc genes in cytokinesis in Drosophila cells (Somma et al.
2002; Goshima and Vale 2003; Kiger et al. 2003; Rogers et al.
2003). Results from our genome-wide screen correlate well
with data from the four smaller screens and other experi-
ments, indicating that the ﬁeld is converging on a consensus
of genes absolutely required for cytokinesis (see Table S5).
Ten genes, reported elsewhere with RNAi binucleate pheno-
types in Drosophila cells, did not score in our screen (INCENP
[Adams et al. 2001]; syx1A [Somma et al. 2002]; proﬁlin, aip1
[CG10724], and capt [Rogers et al. 2003]; and kst, Toll, Toll-4,
bazooka, and kekkon [Kiger et al. 2003]). The dsRNA targeting
these genes, apart from INCENP, passed quality control,
suggesting alternative explanations for the differences be-
tween various RNAi experiments. Three of the smaller
screens were carried out in Drosophila S2 cells (Somma et al.
2002; Goshima and Vale 2003; Rogers et al. 2003), which may
differentially express or require certain proteins. The timing
of RNAi experiments may also contribute to differences that
were observed. We exposed cells to dsRNAs for 4 d, balancing
sufﬁcient depletion with potentially detrimental effects of
prolonged culture and exposure of cells to dsRNA. With an
average cell cycle of 24 h, 4 d may be too short to completely
deplete very stable proteins. For example, depletion of the
Myosin II regulatory light chain (spaghetti squash) resulted in a
weak phenotype, whereas depletion of its complex partner
encoded by zipper, the Myosin II heavy chain, resulted in a
much higher frequency of binucleates. This illustrates the
importance of identifying medium and weak phenotypes.
Genes with weaker binucleate phenotypes may also be
signiﬁcant because depletion of cytokinesis proteins with
multiple functions during the cell cycle can cause arrest prior
to cytokinesis, diminishing the likelihood of detecting the
phenotype in unsynchronized cells. Overlap between our
screen and a recently published proteomic analysis of the
midbody (Skop et al. 2004) highlights the importance of
identifying genes with weaker binucleate phenotypes. For
example, the Arp2/3 complex was not thought to play a role
in cytokinesis in metazoans, but components of this complex
were identiﬁed in both approaches. Eventually, a combina-
tion of different methods will result in a deﬁnitive list of all
proteins involved in cytokinesis.
Systematic Comparisons between RNAi and Small
Molecule Phenotypes
Following our strategy to systematically compare chemical
genetic and functional genomic data, we classiﬁed the data
from both screens into four phenotypic groups (summarized
in Figure 1C and 1D): (1) binucleate cell phenotype only
(Figure 3A), or a combination of binucleate cells with an
additional phenotype of (2) large, diffuse DNA (Figure 3B), (3)
low total cell count (Figure 3C), or (4) microtubule extensions
(Figure 3D). The initial classiﬁcation into four phenotypic
groups was based on the raw screening data, where our
parameters were whole cell, DNA, or tubulin staining. While
these phenotypic classes are useful for global analysis and
preliminary characterization, there were too many genes in
each group to allow meaningful comparisons between small
molecule and RNAi phenotypes. Therefore, we selected 40
genes and 25 small molecules for more detailed analysis. To
ascertain speciﬁc defects in cytokinesis, we determined by
immunolocalization the behavior of 15 proteins involved in
cytokinesis. Our bank of reagents included antibodies to
proteins that are normally found in the cleavage furrow such
as actin (phalloidin), Anillin, Myosin II, and the septin protein
Peanut; proteins involved in the regulation of cytokinesis
such as Aurora B (Giet and Glover 2001), RhoA, Pebble
(Prokopenko et al. 1999), and Polo kinase (Tavares et al.
1996); proteins involved in other aspects of cytokinesis like
Diaphanous, Lava-lamp (Sisson et al. 2000), and Pavarotti; and
proteins that report on the stage of cytokinesis or the state of
the cell cycle such as Lamin (Risau et al. 1981), phospho-
Histone H3, and tubulin. As a speciﬁc example of this
detailed analysis, the phenotypes for Aurora B kinase and
CG4454 are discussed below.
Small Molecules Can Result in Additional Phenotypes
We identiﬁed phenotypes common to both datasets, but
the detailed phenotypic analyses did not match exactly, with
more phenotypic subclasses distinguished with the small
molecules. Two considerations may account for the existence
of additional phenotypic categories for small molecules. One
is timing. During our detailed secondary analysis, we added
small molecules to cells for variable amounts of time (3 h to
48 h). When cells were exposed to a drug for a short time, we
were able to analyze localization of furrow components
immediately after cytokinesis failure. These phenotypes
became less apparent upon longer exposure because the long
delay gave cells the opportunity to disassemble residual
furrow structures. When cells were exposed to dsRNAs for
days, long, variable delays between cytokinesis failure and
Figure 3. Phenotypic Classes
The phenotypic classes are (A) binucleate (CG10522 RNAi) and
binucleate with (B) large, diffuse DNA (aurora B RNAi), (C) low cell
count (RpS18 RNAi), or (D) microtubule extensions (Act5C RNAi). In
(A), (B), and (C), the cytoplasm (tetramethylrhodamine stain) of Kc167
cells is shown in red and DNA in green. In (D), tubulin is shown in red
and DNA in green. See Table S2 for full classiﬁcation.
DOI: 10.1371/journal.pbio.0020379.g003
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could be revealed by subsequent real-time imaging experi-
ments (Goshima and Vale 2003). The other consideration is
potential gain-of-function effects of small molecules. For
example, a natural product extract from Cowania mexicana
containing a cucurbitacin (M. Fujita and J. Clardy, personal
communication) caused clusters of ﬁlamentous actin to
accumulate in interphase cells, in addition to completely
blocking cytokinesis. Since no dsRNA caused this phenotype,
we suspect it is a gain-of-function effect of the small
molecule, whose mechanism we will pursue.
Two Sub-Phenotypes Correlate in Both Small Molecule
and RNAi Datasets
Systematic comparison between the phenotypic categories
based on detailed immunoﬂuorescence analysis of both
screens did, however, allow us to connect small molecules to
two speciﬁc pathways involved in cytokinesis, namely actin
cortex integrity and the Aurora B pathway. Both dsRNAs and
small molecules that weakened the actin cortex caused
microtubule-rich extensions to protrude from interphase
cells as well as failure of cytokinesis (Figure 4). These included
dsRNAs targeted against several actin genes (see Table S2)
and three natural product small molecules known to target
actin that were present in our small molecule collection
(cytochalasin D, jasplakinolide, and swinholide A [from Ircinia
ramosa extract]). This sub-phenotype represents a portion of
the genes identiﬁed as ‘‘binucleate with microtubule exten-
sions’’ shown in Figure 3D.
A second phenotypic class exhibited a high incidence of
both mitosis and cytokinesis defects, a sub-phenotype of the
category ‘‘binucleate with diffuse DNA’’ (see Figure 3B).
Mitosis was abnormal, with malformed spindles and mis-
aligned chromosomes, resulting in large, diffuse arrange-
ments of DNA in binucleate cells (Figure 5). Individual
depletion of any of three proteins encoded by aurora B,
INCENP, and CG4454, or addition of one small molecule N9-
[1-(3-chloro-4-ﬂuorophenyl)-4-cyano-1H-pyrazol-5-yl]-N,N-
dimethyliminoformamide (binucleine 2; Figure 5), caused this
phenotype.
CG4454 RNAi Phenotype and Localization Matches
Chromosomal Passenger Proteins
Aurora B, INCENP (Adams et al. 2001), and Survivin
(Wheatley et al. 2001) form the chromosomal passenger
complex, which also includes CSC-1 in C. elegans (Romano et
al. 2003) and Borealin/Dasra B in humans (Gassmann et al.
2004; Sampath et al. 2004). Aurora B kinase plays a number of
roles during mitosis (Carmena and Earnshaw 2003), including
phosphorylating Histone H3 on Ser-10 (Giet and Glover
2001) and detecting errors in chromosome attachment in
mitosis (Lampson et al. 2004), and performs an essential, but
poorly understood, function in cytokinesis. Chromosomal
passenger proteins localize to the inner centromere during
mitosis and move to the interzonal microtubules, the cleavage
furrow, and eventually the midbody during cytokinesis.
Because the sequences that targeted CG4454 and aurora B
both had 21-bp overlaps with other genes in the dsRNA
collection we screened (see Table S3), we remade dsRNA
targeting different areas of these two genes and observed no
change in phenotype. Since RNAi depletion of the new gene
we discovered in our screen, CG4454, resulted in the same
phenotype as depletion of aurora B and INCENP, we
hypothesized that it could be a new member of the
chromosomal passenger complex. We constructed green
ﬂuorescent protein (GFP) fusion proteins to both C- and N-
termini of CG4454. CG4454-GFP exhibited the signature
localization of a passenger protein and co-localized with
Aurora B throughout mitosis and cytokinesis (Figure 6),
suggesting that it might be complexed to Aurora B. RNAi
depletion of CG4454 or aurora B resulted in an absence of
phosphorylated Histone H3 on mitotic chromosomes (Figure
7, bottom row), further supporting the participation of
CG4454 in the chromosomal passenger complex. Although
CG4454 amino acid sequence reveals a remote similarity with
Borealin/Dasra B (Gassmann et al. 2004), it is unclear at this
point whether CG4454 is its Drosophila homolog. Unlike
CG4454, RNAi depletion of Borealin does not signiﬁcantly
reduce Histone H3 phosphorylation (Gassmann et al. 2004). It
might not be possible to conﬁrm whether CG4454 and
Borealin are related until structural information becomes
available. However, to prevent further confusion in naming
conventions, we have decided to tentatively name CG4454
Borealin-related (Borr).
Figure 4. Kc167 Cells Exposed to dsRNA Targeting Act5C or to
Cytochalasin D
The cells were exposed to dsRNA targeting Act5C for 4 d (A) or to
cytochalasin D at 5 lM for 48 h (B). Tubulin is shown in red, DNA in
green.
DOI: 10.1371/journal.pbio.0020379.g004
Figure 5. Kc167 Cells Untreated or Exposed to aurora B dsRNA, borr
(CG4454) dsRNA, or Binucleine 2
TMR-stained cells were untreated, or treated with dsRNA for 4 d or
binucleine 2 (50 lM) for 2 d. TMR is shown in red, DNA in green. The
chemical structure of binucleine 2 is also shown.
DOI: 10.1371/journal.pbio.0020379.g005
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Complex Phenotypes
We compared the phenotypes caused by RNAi depletion of
aurora B and borr to treatment of cells with binucleine 2 using
immunoﬂuorescence. The phenotypes were very similar, as
judged by perturbation of localization or expression of 14 of
the 15 markers used in our detailed analysis (Figure S1),
suggesting that the two genes and binucleine 2 perturb a
similar step in cytokinesis. The only difference we observed
was localization of the chromosomal passenger protein
INCENP (Figure 7, top row). No INCENP staining at any cell
site was detected in borr-depleted cells, suggesting that Borr is
required for INCENP localization. This phenotype was also
observed in Borealin-depleted cells (Gassmann et al. 2004). In
contrast, we observed INCENP accumulations in binucleine
2–treated and aurora B–depleted cells. INCENP localizes to
the chromosome arms during prometaphase in aurora B–
depleted cells, which is consistent with reported observations
(Adams et al. 2001). In cells exposed to binucleine 2, INCENP
aggregated (Figure 7, top row), but did not appear to co-
localize with Aurora B or DNA. Given its effect on INCENP
localization, binucleine 2 might be a useful tool to study the
localization and movement of the Aurora B complex during
mitosis and cytokinesis, since the factors that regulate these
processes remain obscure. In total, binucleine 2 shares
phenotypes with aurora B RNAi and affects localization of
INCENP, a member of the Aurora B complex, suggesting that
binucleine 2 targets the Aurora pathway. Small molecules can
target and inhibit protein activity directly, whereas dsRNAs
target destruction of mRNA. This difference in mechanism
between small molecule inhibition and RNAi could account
for the variation in INCENP localization we observed. The
speciﬁc activity of binucleine 2, however, is very highly
related to its structure. We assessed the effect of several
similar compounds and found that none were more active
than binucleine 2, while most had very little activity (Figure
S2).
To test whether binucleine 2 inhibits Aurora B kinase
function, we monitored Histone H3 phosphorylation on Ser-
10 in mitotic cells (Giet and Glover 2001). When cells were
exposed to binucleine 2, phospho-Histone H3 was absent on
chromosomes in mitotic cells (Figure 7, bottom row). To get a
quantitative measure of both the concentration of binucleine
2 required and the speed of its action, we assayed about
10,000 cells per time point and concentration for phospho-
Histone H3 staining by immunoﬂuorescence (Figure 8). We
were unable to detect phospho-Histone H3 in cells treated
with 25 lM or 100 lM binucleine 2 for only 30 min, while the
percentage of cells exhibiting phospho-Histone H3 staining
decreased over time in cells treated with binucleine 2 at 1 lM
and 5 lM (Figure 8). While binucleine 2 inhibits Aurora B–
dependent phosphorylation, it is not a general kinase
inhibitor. Binucleine 2 did not inhibit cyclin-dependent-
kinase-dependent entry into mitosis and had no effect on
bulk phosphorylation activity in a Drosophila cell extract (data
not shown). Altogether, phenotypic similarities between loss-
Figure 6. Kc167 Cells Transfected with Borr-
GFP
In the top row, cells in metaphase,
anaphase, and cytokinesis are shown.
Borr-GFP is shown in green, tubulin in
red, and DNA in blue. The bottom row
shows cells in metaphase and cytokinesis.
Borr-GFP is shown in green, Aurora B in
red, and DNA in blue.
DOI: 10.1371/journal.pbio.0020379.g006
Figure 7. Kc167 Cells Untreated or Exposed
to aurora B dsRNA, borr (CG4454) dsRNA, or
Binucleine 2
INCENP-stained cells in the top row
were untreated or treated with aurora B
dsRNA for 5 d, borr (CG4454) dsRNA for
3 d, or binucleine 2 (20 lM) for 4 h.
Phospho-Histone H3 stained cells in the
bottom row were untreated or treated
with dsRNA for 4 d or binucleine 2 (20
lM) for 4 h. White arrows indicate
absence of phospho-Histone H3 staining
in the failed mitotic ﬁgures.
DOI: 10.1371/journal.pbio.0020379.g007
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Parallel Chemical and RNAi Screensof-function for Aurora B and binucleine 2 strongly suggest
that binucleine 2 targets a protein involved in the Aurora B
pathway. Several small molecule inhibitors of Aurora kinases
have been reported, although their chemical scaffolds are
different from binucleine 2. These small molecules are not
active in ﬂy cells, while binucleine 2 is inactive in mammalian
systems (data not shown). Aurora kinase levels are elevated in
some tumors, making these proteins a potential target for
cancer therapy. Interestingly, lower binucleine 2 concen-
tration or shorter Aurora B RNAi treatment favors binucleate
formation, while higher drug concentration and longer
incubation for RNAi results in a relative increase in large
cells with diffuse DNA. Thus, the cytokinesis function of the
Aurora pathway may be more sensitive to inhibition than its
mitosis function. This observation may be important for
understanding the response of cancer cells to Aurora
inhibitors now entering clinical trials (Harrington et al. 2004).
Conclusion
In summary, our parallel screening approach succeeded in
identifying new proteins involved in cytokinesis, and new
small molecules that inhibit it. We identiﬁed 214 proteins
important for cytokinesis, including 25 previously uncharac-
terized predicted proteins. Depletion of one new gene, borr,
had a profound effect on cytokinesis. Borr exhibits the
signature localization of a chromosomal passenger protein
and co-localizes with Aurora B kinase throughout the cell
cycle. We also uncovered a potential role of the COPI
coatomer complex in cytokinesis. By comparative phenotypic
analysis we were able to show that one class of small
molecules targets actin cortex integrity, and another the
Aurora B pathway. A third class of small molecules, whose
phenotype has no RNAi counterpart, presumably causes gain-
of-function effects. Traditional methods like afﬁnity chro-
matography and enzyme inhibition assays will be required to
describe the precise biochemical mechanisms of these new
cytokinesis inhibitors, but the information already gained
from comparative screening will focus this work and allow
rapid conﬁrmation or invalidation of candidate biochemical
targets.
The problem of target identiﬁcation has been one of the
main barriers to more widespread use of phenotype-based
screening in drug discovery. As functional genomic data and
systematic RNAi resources become widely available for
human cells, parallel screening approaches like the one we
describe could be used to discover leads for therapeutic drugs
as well as research reagents.
Materials and Methods
Small molecule screen. 20,000 Drosophila Kc167 cells in 40 llo f
medium (Schneider’s Drosophila Medium [GIBCO, San Diego,
California, United States] supplemented with 10% heat-inactivated
fetal bovine serum [HyClone, South Logan, Utah, United States] and
penicillin/streptomycin [Cellgro, Mediatech, Herdon, Virginia,
United States]) were added to each well using a MultiDrop 384
(Thermo Electron, Waltham, Massachusetts, United States) liquid
dispenser and incubated at 24 8C overnight. Then, 100 nl of
compound stocks dissolved in DMSO at approximately 10 mg/ml
was added using the pin transfer robot at the Institute of Chemistry
and Cell Biology at Harvard Medical School (http://iccb.med.harvard.
edu). Cells were incubated at 24 8C for 48 h. All ﬁxation, staining, and
washing steps were carried out using a MultiDrop liquid dispenser
and 24-channel wand (V&P Scientiﬁc, San Diego, California, United
States) for liquid removal. Cells were ﬁxed and permeabilized in 40 ll
of 100 mM Pipes/KOH (pH 6.8), 10 mM EGTA, 1 mM MgCl2, 3.7%
formaldehyde, and 0.2% TritonX-100 for 15 min and washed in 50 ll
of PBS. The cytoplasm was stained with 40 ll of 0.5 lg/ml NHS-
tetramethylrhodamine (TMR, 5-[and-6]-carboxytetramethylrhod-
amine, succinimidyl ester C-1171, Molecular Probes, Eugene, Oregon,
United States) in PBS for 15 min. Subsequently, 40 llo f5lg/ml
Hoechst 33342 (Sigma, St. Louis, Missouri, United States) in TBST
(TBS with 1% TritonX-100) was added for 30 min. This step stains the
DNA and quenches excess NHS ester to ensure uniform TMR
staining. Cells were washed twice with 40 ll of TBST and sealed with
aluminum seals (Costar 6570, Corning, Corning, New York, United
States) for image acquisition.
Pyrene–actin assay. Pyrene-labeled actin (2 lM, ﬁnal concentra-
tion; 80 ll, ﬁnal volume) was added to 10 mM HEPES (pH 7.7), 2 mM
MgCl2, 100 lM CaCl2, 100 mM KCl, 5 mM EGTA, 200 lM ATP, and 10
lM small molecule. Pyrene–actin polymerization was followed by
ﬂuorescence spectroscopy over 45 min. An increase in ﬂuorescence
indicates actin polymerization. Adapted from Peterson et al. (2001).
RNAi screen. dsRNAs were aliquoted into black, clear-bottom 384-
well plates (Costar 3712, Corning) at the Drosophila RNAi Screening
Center at Harvard Medical School (http://www.ﬂyrnai.org). Each well
contained 5 ll of approximately 0.05 lg/ll dsRNA in water. 10,000
Drosophila Kc167 cells in 10 ll of serum-free Schneiders’s Drosophila
Medium were added to each well containing dsRNA using a
MultiDrop liquid dispenser. After 1 h of incubation at room
temperature, 30 ll of medium (Schneider’s Drosophila Medium
supplemented with 10% heat-inactivated fetal bovine serum and
penicillin/streptomycin) was added. The plates were sealed or placed
in a humidiﬁed chamber and incubated for 4 d at 24 8C. Fixation,
TMR, and Hoechst staining were carried out as described above for
the small molecule screen. Cells were then blocked in 40 ll of AbDil
(TBST with 2% BSA) for 30 min and stained overnight at 4 8C with 20
ll of 1:250 monoclonal anti-tubulin (DM1a, Sigma) and 2 lg/ml Alexa
488 goat anti-mouse antibody (Molecular Probes) in AbDil. Cells were
washed twice with 40 ll of TBST and sealed with aluminum seals
(Costar 6570) for image acquisition. In order to identify weak hits
reliably, the RNAi screen was carried out in triplicate on three
separate occasions.
Image acquisition. Plates from the RNAi and small molecule
screens were imaged using a Universal Imaging (Downingtown,
Pennsylvania, Unites States) AutoScope or a Universal Imaging
Discovery-1. The AutoScope is a Nikon (Tokyo, Japan) TE300
inverted ﬂuorescence microscope with ﬁlter wheel (Lamda10-2,
Sutter Instruments, Novato, California, United Stats), x-y stage (Prior
H107N300), piezoelectric-motorized objective holder (P-723.10,
Physik Instruments, Downingtown, Pennsylvania, United States),
and a CCD camera (OrcaER, Hamamatsu, Hamamatsu City, Japan).
MetaMorph software (Universal Imaging) running the Screen
Acquisition drop-in allowed coordination of software-based autofo-
Figure 8. Time- and Concentration-Dependence of Binucleine 2
Kc167 cells were treated with 1 lM, 5 lM, 25 lM, or 100 lM binucleine
2. Phospho-Histone H3 staining was assessed at different time points.
Binucleine 2 at 100 nM and 300 nM was also tested and showed no
effect (data not shown).
DOI: 10.1371/journal.pbio.0020379.g008
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Parallel Chemical and RNAi Screenscusing, movement between wells, imaging, and image evaluation. Two
images per well were acquired in each of two (small molecule screen)
or three (RNAi screen) channels using a 20x objective with 2 3 2
binning.
Scoring of images. Given the need for greater accuracy in an
annotation screen, the RNAi images were initially scored by visual
inspection. We looked at two images per well from two independent
datasets (datasets 2 and 3, approximately 85,000 images) and noted
wells with elevated binucleate levels. To determine the percentage of
binucleate cells per image, we used the Integrated Morphometry
feature in the MetaMorph software to count the number of nuclei per
image and then manually counted the number of binucleate cells. We
collected two images per assay well and report the level of binucleates
per well as an average of both images. Because the level of binucleates
can vary depending on the location of the well in the assay plate or
the position of the assay plate in a stack of plates, we decided to
compare each proposed hit well to its two neighboring wells to
prevent false positives or negatives due to local variations. If a
neighboring well also exhibited a phenotype, we chose the next
neighbor for our analysis. Although we performed the screen in
triplicate, we were only able to apply this analysis to two datasets
because the cells in the third screen were too clustered to use
automated cell counting. It was possible, however, to estimate the
binucleate level in the third dataset by visual inspection. We only
scored a phenotype if it repeated in at least two experiments, and the
vast majority of phenotypes repeated in all three datasets. In a weakly
penetrant phenotype the binucleate level was increased by more than
1.25-fold relative to the average of both neighboring wells. In a
medium penetrance phenotype the binucleate level was above 4%, or
four times as high as the neighboring wells. In a strongly penetrant
phenotype the binucleate level was above 15%.
Borr-GFP cloning and transfection. For the C-terminal fusion
protein, Borr (CG4454) cDNA (LD36125) was cloned into the EcoRI
and KpnI sites of pEGFP-C1 (Clontech, Palo Alto, California, United
States), cut with NheI and KpnI, and ligated into pPacPL (Krasnow et
al. 1989). For the N-terminal fusion, CG4454 digested with SpeI and
HindIII, pEGFP-N1 (Clontech) digested with NotI and HindIII, and
pPacPL digested with SpeI and NotI were ligated in a triple ligation
reaction. Kc167 cells were transfected with these constructs using
Insect GeneJuice transfection reagent (Novagen, Madison, Wisconsin,
United States) according to the manufacturer’s instructions and were
used for live cell imaging and immunoﬂuorescence 6–7 d after
transfection.
Immunoﬂuorescence analysis. Cells were exposed to dsRNA or
small molecules, ﬁxed, and stained as described in the screening
protocols. Cells were stained with TRITC-labeled phalloidin (Sigma)
to visualize actin or antibodies to the following proteins (data not
shown): Anillin, Aurora B (a gift from D. Glover), Diaphanous,
INCENP (a gift from W. Earnshaw), Lamin (a gift from H.
Saumweber), Lava-lamp, Myosin II, Pavarotti, Peanut, Pebble (a gift
from H. Bellen), phospho-Histone H3 (Upstate Biotechnology, Lake
Placid, New York, United States), Polo (a gift from D. Glover), Rho1
(from the Developmental Studies Hybridoma Bank) and tubulin
(DM1a, Sigma).
Synthesis of N9-[1-(3-chloro-4-ﬂuorophenyl)-4-cyano-1H-pyrazol-5-
yl]-N,N-dimethyl iminoformamide (binucleine 2). Since binucleine 2 is
no longer available commercially, we resynthesized it (see Figure S3):
3-chloro-4-ﬂuorophenylhydrazine hydrochloride (compound 1 in
Figure S3) (500 mg, 2.5 mmol, Alfa Aesar, Karlsruhe, Germany) and
ethoxymethylenemalononitrile (compound 2 in Figure S3) (305 mg,
2.5 mmol, Sigma-Aldrich, St. Louis, Missouri, United States) were
reﬂuxed in 3 ml of ethanol for 4 h. The resulting pyrazol (compound
3 in Figure S3) was partially puriﬁed by recrystallization from
ethanol. Pyrazol (140 mg, 0.5 mmol) and N,N-dimethylformamide
dimethyl acetal (150 ll, 1 mmol, Aldrich) were reﬂuxed in ethanol for
1 h. The product (binucleine 2) (compound 4 in Figure S3) was
recrystallized from ethanol.
1H NMR (500 MHz, (CD3)2SO) d 8.29 (s, 1
H), 8.06 (dd, J1 = 2.7 Hz, J2 = 6.8 Hz, 1 H), 8.03 (s, 1 H), 7.84–7.81 (m,
1 H), 7.55 (t, J = 9.2 Hz, 1 H), 3.14 (s, 3 H), 3.00 (s, 3 H). ESI-MS
calculated for C13H11ClFN5 291, [M þ H]
þ found 292.
Dose response of binucleine 2. Kc167 cells were treated with 100
nM, 300 nM, 1lM, 5lM, 25lM, or 100 lM of binucleine 2 and ﬁxed
after 15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, or 4h.
After staining with phospho-Histone H3 antibody (Upstate), tubulin
(DM1a, Sigma), and DNA and then imaging, cells with phospho-
Histone H3 staining were counted. The total number of cells was
counted using the Integrated Morphometry feature in the Meta-
Morph software, and the percentage of cells with H3 staining was
calculated and is plotted in Figure 8. Approximately 4,000–5,000 cells
per experiment were assessed in two separate experiments for each
time point.
Supporting Information
Figure S1. Examples of Detailed Secondary Analysis Using Immuno-
ﬂuorescence
Cells were untreated or treated with binucleine 2 (100 lM, 48 h) or
dsRNA corresponding to aurora B or borr (CG4454). Cells were stained
with TRITC-labeled phalloidin to visualize actin, or antibodies
against Anillin, tubulin, Lava-lamp, or Lamin. Lamin-stained cells
were treated with binucleine 2 (100 lM) for 24 h.
Found at DOI: 10.1371/journal.pbio.0020379.sg001 (4.5 MB TIF).
Figure S2. Structure Activity Relationships for Binucleine 2
Found at DOI: 10.1371/journal.pbio.0020379.sg002 (49KB DOC).
Figure S3. Synthesis of Binucleine 2
Found at DOI: 10.1371/journal.pbio.0020379.sg003 (32 KB DOC).
Table S1. Small Molecule Phenotypes and Structures
Kc167 cells were exposed to small molecules at 100 lM, 30 lM, or 10
lM for 48 h. In a weakly penetrant phenotype (w), the binucleate level
was increased by at least 1.25-fold above background. In a medium
penetrance phenotype (m), the binucleate level was above 4%, and in
a strongly penetrant phenotype (s), the binucleate level was above
15%, while the average binucleate level was approximately 1%. In the
binucleate phenotype column, ‘‘binucleate’’ indicates binucleate cells
only, ‘‘diffuse DNA,’’ binucleate cells with large, diffuse DNA, ‘‘lc,’’
binucleate cells with low cell count, and ‘‘MT ext,’’ binucleate cells
with microtubule extensions. HeLa and BSC-1 cells were exposed to
small molecules at 30 lM for 24 h. Growth inhibition in drug-sensitive
S. cerevisiae RDY98 (Mat a, erg6DTRP1
cg, pdr1DKAN, pdr3DHIS5þ,
ade2, trp1, his3, leu2, ura3, can1) was measured at a small molecule
concentration of 250 lM after an overnight exposure.
Found at DOI: 10.1371/journal.pbio.0020379.st001 (159 KB DOC).
Table S2. List of Targeted Genes Identiﬁed by Binucleate Cells in the
RNAi Screen
The ‘‘DRSC dsRNA ID’’ is an internal dsRNA ID number. In the
potency column, ‘‘s’’ represents strong, ‘‘m,’’ medium and ‘‘w,’’ weak
penetrance of the binucleate cell phenotype. In the phenotypic
classiﬁcation column, ‘‘binucleate’’ indicates binucleate cells only,
‘‘diffuse DNA,’’ binucleate cells with large, diffuse DNA, ‘‘lc,’’
binucleate cells with low cell count, and ‘‘MT ext,’’ binucleate cells
with microtubule extensions. Six genes were independently identiﬁed
in multiple wells, either scored twice—CG10522, cycA, Pp4-19C, RpL32,
Tra1, and Ubi-63E—or three times—crn.
Found at DOI: 10.1371/journal.pbio.0020379.st002 (141 KB DOC).
Table S3. Information about Genes with Binucleate Phenotypes and
Quantitative Analysis of Binucleate Phenotypes
Gene names, FlyBase IDs, Gene Ontology annotations, forward and
reverse primers, and amplicon lengths are shown. ‘‘HFA amplicon’’
and ‘‘DRSC dsRNA ID’’ are internal dsRNA identiﬁers. The number
of potential secondary targets based on 21 nucleotide fragments is
the number of genes that have at least one length of 21 bp or more
with matching sequence of 21 bp or more of this amplicon. The
criteria used in this analysis are such that it may be prone to false
positives for secondary targets. The binucleate percentage per well,
the relative increase in binucleates relative to the neighboring wells
(1.25 = 25% increase), cell number per well, and relative increase or
decrease in cell number relative to the neighboring wells are shown
for datasets 1 and 2. Annotations for dataset 3 are only shown when
they help to deﬁne a particular phenotype.
Found at DOI: 10.1371/journal.pbio.0020379.st003 (97KB XLS).
Table S4. Genes That Scored in the RNAi Screen Sorted by Assigned
Functional Groups
Functional groups are based on the predicted function as reported by
FlyBase (new annotation excluded).
Found at DOI: 10.1371/journal.pbio.0020379.st004 (90 KB DOC).
Table S5. Genes Reported to Be Involved in Cytokinesis and Genes
That Resulted in Strong and Medium RNAi Phenotypes
Found at DOI: 10.1371/journal.pbio.0020379.st005 (181 KB DOC).
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